DataVXACS Applied Nano MaterialsPaper
journal article·2022-07-22

pH-Responsive Chitosan-Adorned Niosome Nanocarriers for Co-Delivery of Drugs for Breast Cancer Therapy

Sara Karimifard, Niloufar Rezaei, Elham Jamshidifar, Shahryar Moradi Falah Langeroodi, Mohammadreza Abdihaji, Afsoun Mansouri, Mahshid Hosseini, Nima Ahmadkhani, Ziba Rahmati, Maryam Heydari, Massoud Vosough, Iman Akbarzadeh, Ebrahim Mostafavi

ACS Applied Nano Materials· Volume 5· Issue 7
Publisher page
Source abstract

Abstract

Breast cancer incidence has increased in recent decades. In the present study, an optimum formulation of chitosan (CS)-adorned niosome-based nanocarriers for co-delivery of doxorubicin (DOX) and vincristine (VIN) was developed for the treatment of breast cancer to reduce drug doses and overcome multidrug resistance. The three-level Box–Behnken method was utilized to optimize the particles in terms of size, polydispersity index (PDI), entrapment efficacy (EE (%)), and percent of drug release (%). The release rate of two drugs from CS-adorned nanoparticles (DOX+VIN/Nio/CS) in acidic and physiological pH is less than uncoated niosome (DOX+VIN/Nio). In addition, acidic pH increases the release rate of drugs from these formulations. The size, polydispersity index, and entrapment efficacy of nanoparticles were more stable at 4 °C compared to 25 °C. MTT assay showed that the IC50 of DOX+VIN/Nio/CS is the lowest value between all fabricated formulations. We evaluated the cancer metastasis and migration (MMP2, MMP9) and transcriptional targets for the tumor suppressor protein (Bax, Bcl2) that induces cell cycle arrest or apoptosis in response to DNA. Bax gene was highly expressed, while the Bcl2, MMP2, and MMP9 genes decreased in DOX+VIN/Nio/CS compared to control, free forms of DOX, VIN, DOX+VIN, and DOX+VIN/Nio. DOX+VIN/Nio/CS inhibited cell migration and increased apoptosis, cell uptake, and endocytosis in human SKBR3 breast cancer cells compared to DOX, VIN, DOX+VIN. These in vitro data are promising to treat breast cancer with advanced pH-responsive drug release nanoformulations.
Source: openalex_inverted_index · Quality: baseline

Research context

Nanomaterials

OpenAlex topics: Nanoparticle-Based Drug Delivery · Advancements in Transdermal Drug Delivery · Dendrimers and Hyperbranched Polymers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Stem Cells Research Center, Tissue Engineering and Regenerative Medicine Institute, Islamic Azad University, Central Tehran Branch, Tehran 1955847781, Iran

Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran 16635148, Iran

Department of Pharmaceutical Nanotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 1416753955, Iran

Pharmaceutics Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman 7616913555, Iran

Department of Biology, The Center for Genomics and Bioinformatics, Indiana University, Bloomington, Indiana 47405-7000, United States

School of Pharmacy and Pharmaceutical Sciences, Tehran Medical Sciences, Islamic Azad University, Tehran 19395-1495, Iran

Department of Chemical and Petroleum Engineering, Sharif University of Technology, Tehran 1458889694, Iran

School of Chemical, Biological and Environmental Engineering, Oregon State University, Corvallis, Oregon 97331, United States

Department of Chemical Engineering, University of South Carolina, Columbia, South Carolina 29208, United States

Department of Cell and Molecular Biology, Faculty of Biological Science, University of Kharazmi, Tehran 199389373, Iran

Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, California 94305, United States

Department of Medicine, Stanford University School of Medicine, Stanford, California 94305, United States

Funding

National Institute of Biomedical Imaging and Bioengineering

References (65)

Show source-provided references
1. 10.1021/acs.chemrev.6b0007310.1021/acs.chemrev.6b00073 ↗
2. 10.1186/bcr63410.1186/bcr634 ↗
3. 10.1016/j.omega.2018.09.00910.1016/j.omega.2018.09.009 ↗
4. 10.1016/j.semcancer.2019.10.02010.1016/j.semcancer.2019.10.020 ↗
5. 10.1186/s12951-018-0392-810.1186/s12951-018-0392-8 ↗
6. 10.1101/2020.12.16.2024837310.1101/2020.12.16.20248373 ↗
7. 10.1186/s12645-021-00085-910.1186/s12645-021-00085-9 ↗
8. 10.3906/biy-2010-6210.3906/biy-2010-62 ↗
9. 10.1021/nl080141f10.1021/nl080141f ↗
10. 10.1016/j.biopha.2021.11170810.1016/j.biopha.2021.111708 ↗
11. 10.1097/MPH.000000000000211410.1097/MPH.0000000000002114 ↗
12. 10.1007/s11095-016-1924-210.1007/s11095-016-1924-2 ↗
13. 10.1038/s41598-020-64760-410.1038/s41598-020-64760-4 ↗
14. 10.1155/2018/684797110.1155/2018/6847971 ↗
15. 10.1021/acsomega.0c0535010.1021/acsomega.0c05350 ↗
16. 10.1186/s12951-018-0351-410.1186/s12951-018-0351-4 ↗
17. 10.3390/biology1003017310.3390/biology10030173 ↗
18. 10.1021/nn404481f10.1021/nn404481f ↗
19. 10.3390/pharmaceutics1204037110.3390/pharmaceutics12040371 ↗
20. 10.1038/nnano.2014.6210.1038/nnano.2014.62 ↗
21. 10.1002/jbm.b.3463610.1002/jbm.b.34636 ↗
22. 10.1080/25740881.2019.160264510.1080/25740881.2019.1602645 ↗
23. 10.30699/mmlj17.4.1.3910.30699/mmlj17.4.1.39 ↗
24. 10.1039/c2jm30501a10.1039/c2jm30501a ↗
25. 10.1080/21691401.2018.143058410.1080/21691401.2018.1430584 ↗
26. 10.1016/j.ijpharm.2010.01.01810.1016/j.ijpharm.2010.01.018 ↗
27. 10.1007/s11094-020-02100-610.1007/s11094-020-02100-6 ↗
28. 10.1081/DDC-12001535110.1081/DDC-120015351 ↗
29. 10.1166/jbn.2016.226310.1166/jbn.2016.2263 ↗
30. 10.2147/IJN.S33709310.2147/IJN.S337093 ↗
31. 10.1017/S204047002000001110.1017/S2040470020000011 ↗
32. 10.2217/nnm-2020-016910.2217/nnm-2020-0169 ↗
33. 10.1016/j.ctrv.2010.05.00410.1016/j.ctrv.2010.05.004 ↗
34. 10.1097/FPC.0b013e32833ffb5610.1097/FPC.0b013e32833ffb56 ↗
35. 10.1007/s00280-012-2042-410.1007/s00280-012-2042-4 ↗
36. 10.22270/jddt.v11i4-S.490710.22270/jddt.v11i4-S.4907 ↗
37. 10.1016/j.imr.2014.10.00410.1016/j.imr.2014.10.004 ↗
38. 10.1016/j.ejpb.2014.01.00610.1016/j.ejpb.2014.01.006 ↗
39. 10.1529/biophysj.107.10404210.1529/biophysj.107.104042 ↗
40. 10.1080/0898210050036413110.1080/08982100500364131 ↗
41. 10.3109/02652048.2010.50657910.3109/02652048.2010.506579 ↗
42. 10.1007/s40005-014-0121-810.1007/s40005-014-0121-8 ↗
43. Akbari V. · Avicenna J. Med. Biotechnol. · 2015 · 7 · 69
44. 10.1016/0014-5793(90)81487-910.1016/0014-5793(90)81487-9 ↗
45. 10.1208/s12249-016-0622-z10.1208/s12249-016-0622-z ↗
46. 10.1016/j.jfoodeng.2013.02.02010.1016/j.jfoodeng.2013.02.020 ↗
47. 10.1016/j.colsurfa.2014.07.04210.1016/j.colsurfa.2014.07.042 ↗
48. 10.1186/s12645-021-00085-910.1186/s12645-021-00085-9 ↗
49. 10.1155/2014/95974110.1155/2014/959741 ↗
50. 10.2147/ijn.s803010.2147/ijn.s8030 ↗
51. Shaker D. S. · Int. J. Pharm. Pharm. Sci. · 2013 · 5 · 344
52. 10.1039/C7RA07834J10.1039/C7RA07834J ↗
53. 10.1186/s12645-020-00059-310.1186/s12645-020-00059-3 ↗
54. 10.1016/j.nano.2020.10232010.1016/j.nano.2020.102320 ↗
55. 10.1186/s12645-020-00059-310.1186/s12645-020-00059-3 ↗
56. 10.1080/00914037.2015.103066310.1080/00914037.2015.1030663 ↗
57. 10.1039/C7RA01736G10.1039/C7RA01736G ↗
58. 10.1016/j.biocel.2009.01.00210.1016/j.biocel.2009.01.002 ↗
59. 10.1152/physrev.00026.201310.1152/physrev.00026.2013 ↗
60. 10.1101/cshperspect.a00865610.1101/cshperspect.a008656 ↗
61. 10.3390/polym1311171710.3390/polym13111717 ↗
62. 10.4081/ejh.2016.264010.4081/ejh.2016.2640 ↗
63. 10.1080/21691401.2018.145383110.1080/21691401.2018.1453831 ↗
64. 10.1080/21691401.2018.155917910.1080/21691401.2018.1559179 ↗
65. 10.2174/138161282266616102515400310.2174/1381612822666161025154003 ↗